BCR–ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia (original) (raw)

• Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780–3792.
  CAS PubMed Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
  Article CAS PubMed Google Scholar
• Bernstein R . Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988; 25: 20–34.
  CAS PubMed Google Scholar
• Laneuville P, Sun G, Timm M, Vekemans M . Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992; 80: 1788–1797.
  CAS PubMed Google Scholar
• Salloukh HF, Laneuville P . Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 2000; 14: 1401–1404.
  Article CAS PubMed Google Scholar
• Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003; 101: 4583–4588.
  Article CAS PubMed Google Scholar
• Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T . BCR//ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008; 22: 1969–1972.
  Article CAS PubMed Google Scholar
• Dierov J, Sanchez PV, Burke BA, Padilla-Nash H, Putt ME, Ried T et al. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 2009; 23: 279–286.
  Article CAS PubMed Google Scholar
• Skorski T . BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma 2008; 49: 610–614.
  Article CAS PubMed Google Scholar
• Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717–1723.
  Article CAS PubMed Google Scholar
• Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319–327.
  Article CAS PubMed PubMed Central Google Scholar
• Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273–24278.
  Article CAS PubMed Google Scholar
• Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009; 16: 232–245.
  Article CAS PubMed PubMed Central Google Scholar
• Kunkel TA, Bebenek K . DNA replication fidelity. Annu Rev Biochem 2000; 69: 497–529.
  Article CAS PubMed Google Scholar
• Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137.
  Article CAS PubMed Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
  Article CAS PubMed Google Scholar
• Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.
  Article CAS PubMed PubMed Central Google Scholar
• Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66–72.
  Article CAS PubMed PubMed Central Google Scholar
• Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68: 2576–2580.
  Article CAS PubMed Google Scholar
• Canitrot Y, Falinski R, Louat T, Laurent G, Cazaux C, Hoffmann JS et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003; 102: 2632–2637.
  Article CAS PubMed Google Scholar
• Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M et al. Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin Cancer Res 2003; 9: 3722–3730.
  CAS PubMed Google Scholar
• Maru Y, Kobayashi T, Tanaka K, Shibuya M . BCR binds to the xeroderma pigmentosum group B protein. Biochem Biophys Res Commun 1999; 260: 309–312.
  Article CAS PubMed Google Scholar
• Takeda N, Shibuya M, Maru Y . The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci USA 1999; 96: 203–207.
  Article CAS PubMed PubMed Central Google Scholar
• Maru Y, Bergmann E, Coin F, Egly JM, Shibuya M . TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome. Mutat Res 2001; 483: 83–88.
  Article CAS PubMed Google Scholar
• Dierov J, Dierova R, Carroll M . BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 2004; 5: 275–285.
  Article CAS PubMed Google Scholar
• Vigneri P, Wang JY . Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228–234.
  Article CAS PubMed Google Scholar
• Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A et al. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006; 5: 994–1000.
  Article CAS PubMed Google Scholar
• Sliwinski T, Czechowska A, Szemraj J, Morawiec Z, Skorski T, Blasiak J . STI571 reduces NER activity in BCR/ABL-expressing cells. Mutat Res 2008; 654: 162–167.
  Article CAS PubMed Google Scholar
• Slupianek A, Nowicki MO, Koptyra M, Skorski T . BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair 2006; 5: 243–250.
  Article CAS PubMed Google Scholar
• Gaymes TJ, Mufti GJ, Rassool FV . Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002; 62: 2791–2797.
  CAS PubMed Google Scholar
• Pastwa E, Poplawski T, Czechowska A, Malinowski M, Blasiak J . Non-homologous DNA end joining repair in normal and leukemic cells depends on the substrate ends. Z Naturforsch (C) 2005; 60: 493–500.
  Article CAS Google Scholar
• Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, Vaganay S et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001; 97: 2084–2090.
  Article CAS PubMed Google Scholar
• Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV . Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res 2003; 63: 1798–1805.
  CAS PubMed Google Scholar
• Corneo B, Wendland RL, Deriano L, Cui X, Klein IA, Wong SY et al. Rag mutations reveal robust alternative end joining. Nature 2007; 449: 483–486.
  Article CAS PubMed Google Scholar
• Gottlich B, Reichenberger S, Feldmann E, Pfeiffer P . Rejoining of DNA double-strand breaks in vitro by single-strand annealing. Eur J Biochem/FEBS 1998; 258: 387–395.
  Article CAS Google Scholar
• Wang H, Rosidi B, Perrault R, Wang M, Zhang L, Windhofer F et al. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Res 2005; 65: 4020–4030.
  Article CAS PubMed Google Scholar
• Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G . PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006; 34: 6170–6182.
  Article CAS PubMed PubMed Central Google Scholar
• Oshima J, Huang S, Pae C, Campisi J, Schiestl RH . Lack of WRN results in extensive deletion at nonhomologous joining ends. Cancer Res 2002; 62: 547–551.
  CAS PubMed Google Scholar
• Sallmyr A, Tomkinson AE, Rassool FV . Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood 2008; 112: 1413–1423.
  Article CAS PubMed PubMed Central Google Scholar
• Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104: 3746–3753.
  Article CAS PubMed Google Scholar
• Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 4189–4201.
  Article CAS PubMed PubMed Central Google Scholar
• Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999; 274: 12748–12752.
  Article CAS PubMed Google Scholar
• Benson FE, Baumann P, West SC . Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature 1998; 391: 401–404.
  Article CAS PubMed Google Scholar
• Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795–806.
  Article CAS PubMed Google Scholar
• Langland G, Elliott J, Li Y, Creaney J, Dixon K, Groden J . The BLM helicase is necessary for normal DNA double-strand break repair. Cancer Res 2002; 62: 2766–2770.
  CAS PubMed Google Scholar
• Slupianek A, Gurdek E, Koptyra M, Nowicki MO, Siddiqui KM, Groden J et al. BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin. Oncogene 2005; 24: 3914–3922.
  Article CAS PubMed Google Scholar
• Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves CJ et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008; 68: 6884–6888.
  Article CAS PubMed PubMed Central Google Scholar
• Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009; 114: 1813–1819.
  Article CAS PubMed PubMed Central Google Scholar
• Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516–519.
  Article CAS PubMed Google Scholar
• Melo JV, Kumberova A, van Dijk AG, Goldman JM, Yuille MR . Investigation on the role of the ATM gene in chronic myeloid leukaemia. Leukemia 2001; 15: 1448–1450.
  Article CAS PubMed Google Scholar
• Tritarelli A, Oricchio E, Ciciarello M, Mangiacasale R, Palena A, Lavia P et al. p53 localization at centrosomes during mitosis and postmitotic checkpoint are ATM-dependent and require serine 15 phosphorylation. Mol Biol Cell 2004; 15: 3751–3757.
  Article CAS PubMed PubMed Central Google Scholar
• Marx J . Cell biology. Do centrosome abnormalities lead to cancer? Science (New York) 2001; 292: 426–429.
  Article CAS Google Scholar
• Nigg EA . Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev 2001; 2: 21–32.
  Article CAS Google Scholar
• Giehl M, Fabarius A, Frank O, Erben P, Zheng C, Hafner M et al. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Leukemia 2007; 21: 1971–1976.
  Article CAS PubMed Google Scholar
• Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 2005; 19: 1192–1197.
  Article CAS PubMed Google Scholar
• Martin SJ, Lennon SV, Bonham AM, Cotter TG . Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 1990; 145: 1859–1867.
  CAS PubMed Google Scholar
• McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG . BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179–1187.
  CAS PubMed Google Scholar
• Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR . Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998; 16: 1383–1390.
  Article CAS PubMed Google Scholar
• Keeshan K, Mills KI, Cotter TG, McKenna SL . Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001; 15: 1823–1833.
  Article CAS PubMed Google Scholar
• Keeshan K, Cotter TG, McKenna SL . High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia 2002; 16: 1725–1734.
  Article CAS PubMed Google Scholar